Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.
Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.
Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States
Research Site, Toronto, Ontario, Canada
The Children's Hospital, Aurora, Colorado, United States
Morgan Stanley Children's Hospital of NYP, New York, New York, United States
Children's Memorial Hospital, Chicago, Illinois, United States
Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, Limburg, Netherlands
Research Site, Seattle, Washington, United States
Research Site, Leiden, Netherlands
All India Institute of Medical Sciences, New Delhi, Delhi, India
Centre for Human Drug Research, Leiden, Netherlands
Pfizer Investigational Site, Cincinnati, Ohio, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.